DBV Technologies S.A.
DBVT evidence brief
What we can confirm
- BioSniper Score:
- 6.7 / 10
- Market Cap:
- $744.8M
- Lead Asset:
- Viaskin Milk (Phase 3)
What it means
What to watch
Prepared research question
What matters most for DBVT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · DBVT
DBV Technologies S.A. (DBVT) is a clinical-stage biopharmaceutical company developing the Viaskin Peanut epicutaneous immunotherapy patch for peanut allergy, with a focus on children aged 4–7 years.
Key risk: Pre-revenue stage
BioSniper Score
Based on 4 of 6 signals
Market Cap
$744.8M
Cash Runway
—
Lead Asset
Viaskin Milk (Phase 3)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 15 clinical trials for DBV Technologies S.A..
DBV Technologies S.A. (DBVT) is a clinical-stage biopharmaceutical company developing the Viaskin Peanut epicutaneous immunotherapy patch for peanut allergy, with a focus on children aged 4–7 years.
- Cash & equivalents of $174.9M as of 2026-06-30 [sec].
- Total revenue of $0.7M and net income of -$50.4M as of 2026-06-30 [sec].
- Phase 3 VITESSE trial met its primary endpoint in December 2025 [sec_mda · as of 2026-03-26].
- BLA submission for Viaskin Peanut in children aged 4–7 is planned for the third quarter of 2026 [sec_mda · as of 2026-07-16].
- Company raised $386.2 million in capital between March 2025 and January 2026 [sec · filed 2026-05-11].
What works
- Positive Phase 3 VITESSE results: 46.6% of treated children met response criteria vs. 14.8% placebo, with a safety profile consistent with prior studies [sec_mda · as of 2026-03-26].
- Strong financing execution: $386.2M raised from March 2025 to January 2026, extending cash runway into Q3 2027 [sec · filed 2026-05-11][sec_mda · as of 2026-07-16].
- Clear FDA feedback on BLA requirements for Viaskin Peanut in children aged 4–7, providing an executable path to submission [sec_mda · as of 2026-04-30].
What to weigh
- Company remains pre-revenue with $0.7M total revenue and a net loss of $50.4M as of 2026-06-30 [sec].
- BLA submission timing was revised from Q2 to Q3 2026, indicating potential regulatory or operational delays [sec_mda · as of 2026-07-16].
- Cash runway estimates exclude expenditures for programs beyond Viaskin Peanut or potential in-licensing, limiting flexibility [sec_mda · as of 2026-04-30].
- As a clinical-stage company, DBV may need additional funding to support growth and commercialization [sec · filed 2026-05-11].
From the filings
Quoted directly from source documents.
Phase 3 VITESSE trial met its primary endpoint
“VITESSE met its primary endpoint: the lower bound of the 95% confidence interval the difference between treatment arms was 24.5%, exceeding the prespecified threshold of 15%.”
SEC MD&A · March 26, 2026
Cash position as of March 31, 2026
“As of March 31, 2026, Cash & Cash Equivalents are $229.2 million.”
SEC MD&A · April 30, 2026
BLA submission timing revised to Q3 2026
“Following the revised timing of the anticipated BLA submission from the second to the third quarter of 2026”
SEC MD&A · July 16, 2026
Capital raised between March 2025 and January 2026
“the Company raised $386.2 million in capital between March 2025 and January 2026.”
SEC filings · May 11, 2026
Catalyst timeline
- 2018-12-06 · Phase3_Start: EPITOPE Open-label Extension Study — Long-term safety and efficacy study of DBV712 in peanut-allergic children.
- 2023-02-21 · Phase3_Start: VITESSE Trial — Phase 3 double-blind, placebo-controlled study of DBV712 in 4-7-year-old children with peanut allergy.
- 2025-05-31 · Trial_Readout: EPITOPE Open-Label Extension — After 24 months of VP250, 81.3% reached an eliciting dose ≥1000 mg.
- 2025-06-24 · Phase3 — Additional Phase 3 catalyst event (details not fully provided in chunks).
Risks & what to watch (3)›
Key risks
- Pre-revenue stage — Total revenue of only $0.7M and net loss of $50.4M as of 2026-06-30 [sec].
- BLA submission delay — BLA submission pushed from Q2 to Q3 2026, potentially delaying commercialization [sec_mda · as of 2026-07-16].
- Funding dependency — Cash runway estimates exclude costs for programs beyond Viaskin Peanut, limiting strategic flexibility [sec_mda · as of 2026-04-30].
What to watch
- BLA submission for Viaskin Peanut in children aged 4–7, expected in Q3 2026 [sec_mda · as of 2026-07-16].
- FDA review outcome and potential approval decision for Viaskin Peanut.
- Cash runway updates and any additional financing activities [sec_mda · as of 2026-07-16].
- Commercial launch preparations and partnership developments for Viaskin Peanut [sec_mda · as of 2026-07-16].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run DBV Technologies S.A. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available DBV Technologies S.A. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.39 · 0% dilution
Lead: Phase 3
2 candidates
No upcoming catalysts tracked
0 buys · 1 sell (180d)
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 3.1%
- Days to cover
- 7.7
- Shares short
- 1,814,983
- Daily short volume (Oct 12, 2026)
- 39.9%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
DBVT short interestGovernance
Frequently asked questions
What is the AI investment thesis for DBV Technologies S.A.?
DBV Technologies S.A. (DBVT) is a clinical-stage biopharmaceutical company developing the Viaskin Peanut epicutaneous immunotherapy patch for peanut allergy, with a focus on children aged 4–7 years.
What is DBV Technologies S.A.'s lead drug candidate?
DBV Technologies S.A.'s most advanced tracked candidate is Viaskin Milk (Phase 3) for Peanut Allergy.
Who is the CEO of DBV Technologies S.A.?
Mr. Daniel Tassé is the chief executive officer of DBV Technologies S.A. (DBVT).
Where is DBV Technologies S.A. headquartered?
DBV Technologies S.A. (DBVT) is headquartered in Châtillon, France.
What therapeutic areas does DBV Technologies S.A. focus on?
DBV Technologies S.A. develops therapies across Oncology, Neurology, Immunology, Cardiovascular, Respiratory, Dermatology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.